Login to Your Account



Celltech Enlists Biogen To Manufacture Crohn’s Drug

By Nuala Moran


Wednesday, May 1, 2002
LONDON - Celltech Group plc agreed to a deal with Biogen Inc. to take over the manufacturing and share the development and commercialization of CDP 571, which is in Phase III trials for the treatment of Crohn’s disease. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription